Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Mol Cancer Ther. 2014 Sep 25;13(12):3024–3036. doi: 10.1158/1535-7163.MCT-14-0400

Figure 6. Rapamycin enhances antigen specific memory T cell function in GL26 induced glioma in mice.

Figure 6

(a) Ad-Flt3L + Ad-TK/GCV treated mice from figure 5 that survived to 90 days were given a second tumor challenge in the left striatum. Brains, lymph nodes and spleens were collected at indicated time points. (b) – (c) Percentage of CD44+ CD62Lhigh population among tet+ CD8+ T cells in spleen (b) and dLNs (c) at day 89 are shown. (d) – (E) OVA-specific CD8+ T cells (d) and SIINFEKL-induced IFN-γ production by CD8+ T cells (e) in brain tumors 5 days after the second challenge (at day 95). Data was compared using unpaired 2-tailed Student’s t-test. Mean ± SEM are indicated, * p < 0.05. (f) Survivors were rechallenged at day 90 without further treatment. Survival curves were compared using Mantel-Cox test, *** p < 0.005.